Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer
BACKGROUND Prostate specific antigen (PSA) is widely used for prostate cancer screening but its levels are influenced by many non cancer‐related factors. The goal of the study is to estimate the effect of genetic variants on PSA levels. METHODS We evaluated the association of SNPs that were reported...
Saved in:
Published in | The Prostate Vol. 69; no. 4; pp. 419 - 427 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.03.2009
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | BACKGROUND
Prostate specific antigen (PSA) is widely used for prostate cancer screening but its levels are influenced by many non cancer‐related factors. The goal of the study is to estimate the effect of genetic variants on PSA levels.
METHODS
We evaluated the association of SNPs that were reported to be associated with prostate cancer risk in recent genome‐wide association studies with plasma PSA levels in a Swedish study population, including 1,722 control subjects without a diagnosis of prostate cancer.
RESULTS
Of the 16 SNPs analyzed in control subjects, significant associations with PSA levels (P ≤ 0.05) were found for six SNPs. These six SNPs had a cumulative effect on PSA levels; the mean PSA levels in men were almost twofold increased across increasing quintile of number of PSA associated alleles, P‐trend = 3.4 × 10−14. In this Swedish study population risk allele frequencies were similar among T1c case patients (cancer detected by elevated PSA levels alone) as compared to T2 and above prostate cancer case patients.
CONCLUSIONS
Results from this study may have two important clinical implications. The cumulative effect of six SNPs on PSA levels suggests genetic‐specific PSA cutoff values may be used to improve the discriminatory performance of this test for prostate cancer; and the dual associations of these SNPs with PSA levels and prostate cancer risk raise a concern that some of reported prostate cancer risk‐associated SNPs may be confounded by the prevalent use of PSA screening. Prostate 69:419–427, 2009. © 2008 Wiley‐Liss, Inc. |
---|---|
Bibliography: | National Cancer Institute - No. CA105055 CA106523 CA95052 CA129684 P50-CA92629 SPORE istex:E87F8F32ED5B92256971634904B88A89D64E2EA4 Department of Defense - No. PC051264 Swedish Research Council (Medicine) - No. 20095 ArticleID:PROS20908 Swedish Academy of Sciences (Vetenskapsrådet) Fredrik Wiklund and S. Lilly Zheng contributed equally to this work. Swedish Cancer Society - No. 3555 Swedish Cancer Society (Cancerfonden) ark:/67375/WNG-HZC3ZBXP-C ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0270-4137 1097-0045 1097-0045 |
DOI: | 10.1002/pros.20908 |